Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68


Should we be combining local tumor therapies with immunotherapies as standard?

Baues C, Schlaak M, von Bergwelt-Baildon M, Theurich S.

Future Oncol. 2017 Aug;13(18):1573-1575. doi: 10.2217/fon-2017-0150. Epub 2017 Aug 22. No abstract available.


[Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma].

Stranzenbach R, Theurich S, Schlaak M.

Hautarzt. 2017 Sep;68(9):716-720. doi: 10.1007/s00105-017-4023-3. Review. German.


Serotonin Shapes the Migratory Potential of NK Cells - An in vitro Approach.

Zimmer P, Bloch W, Kieven M, Lövenich L, Lehmann J, Holthaus M, Theurich S, Schenk A.

Int J Sports Med. 2017 Oct;38(11):857-863. doi: 10.1055/s-0043-113042. Epub 2017 Aug 7.


Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.

Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.

Cancer Immunol Res. 2017 Sep;5(9):730-743. doi: 10.1158/2326-6066.CIR-16-0236. Epub 2017 Aug 4.


IL-6/Stat3-Dependent Induction of a Distinct, Obesity-Associated NK Cell Subpopulation Deteriorates Energy and Glucose Homeostasis.

Theurich S, Tsaousidou E, Hanssen R, Lempradl AM, Mauer J, Timper K, Schilbach K, Folz-Donahue K, Heilinger C, Sexl V, Pospisilik JA, Wunderlich FT, Brüning JC.

Cell Metab. 2017 Jul 5;26(1):171-184.e6. doi: 10.1016/j.cmet.2017.05.018.


Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.

Lechner A, Schlößer H, Rothschild SI, Thelen M, Reuter S, Zentis P, Shimabukuro-Vornhagen A, Theurich S, Wennhold K, Garcia-Marquez M, Tharun L, Quaas A, Schauss A, Isensee J, Hucho T, Huebbers C, von Bergwelt-Baildon M, Beutner D.

Oncotarget. 2017 Jul 4;8(27):44418-44433. doi: 10.18632/oncotarget.17901.


Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance.

Xu E, Pereira MMA, Karakasilioti I, Theurich S, Al-Maarri M, Rappl G, Waisman A, Wunderlich FT, Brüning JC.

Nat Commun. 2017 May 3;8:14803. doi: 10.1038/ncomms14803.


Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation.

Leuchte K, Schlaak M, Stadler R, Theurich S, von Bergwelt-Baildon M.

Oncol Res Treat. 2017;40(5):262-269. doi: 10.1159/000472257. Epub 2017 Apr 20. Review.


Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors.

Baues C, Trommer-Nestler M, Jablonska K, Bröckelmann PJ, Schlaak M, von Bergwelt-Baildon M, Engert A, Semrau R, Marnitz S, Theurich S.

Immunotherapy. 2017 Mar;9(5):423-433. doi: 10.2217/imt-2017-0002. Review.


Regulatory B10 cells display an altered homoeostasis in acute graft-versus-host disease.

Chakupurakal G, Garcia-Marquez MA, Shimabukuro-Vornhagen A, Kluth S, Schlosser H, Theurich S, Scheid C, Hallek M, Holtick U, von Bergwelt-Baildon M.

Eur J Haematol. 2017 Feb;98(2):128-133. doi: 10.1111/ejh.12810. Epub 2016 Nov 6.


Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity.

Jais A, Solas M, Backes H, Chaurasia B, Kleinridders A, Theurich S, Mauer J, Steculorum SM, Hampel B, Goldau J, Alber J, Förster CY, Eming SA, Schwaninger M, Ferrara N, Karsenty G, Brüning JC.

Cell. 2016 Aug 25;166(5):1338-1340. doi: 10.1016/j.cell.2016.08.010. No abstract available.


Antigen-presenting human B cells are expanded in inflammatory conditions.

Shimabukuro-Vornhagen A, García-Márquez M, Fischer RN, Iltgen-Breburda J, Fiedler A, Wennhold K, Rappl G, Abken H, Lehmann C, Herling M, Wolf D, Fätkenheuer G, Rubbert-Roth A, Hallek M, Theurich S, von Bergwelt-Baildon M.

J Leukoc Biol. 2017 Feb;101(2):577-587. doi: 10.1189/jlb.5A0416-182R. Epub 2016 Aug 17.


Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.

Schlößer HA, Drebber U, Kloth M, Thelen M, Rothschild SI, Haase S, Garcia-Marquez M, Wennhold K, Berlth F, Urbanski A, Alakus H, Schauss A, Shimabukuro-Vornhagen A, Theurich S, Warnecke-Ebertz U, Stippel DL, Zippelius A, Büttner R, Hallek M, Hölscher AH, Zander T, Mönig SP, von Bergwelt-Baildon M.

Oncoimmunology. 2015 Nov 9;5(5):e1100789. doi: 10.1080/2162402X.2015.1100789. eCollection 2016 May.


Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.

Theurich S, Rothschild SI, Hoffmann M, Fabri M, Sommer A, Garcia-Marquez M, Thelen M, Schill C, Merki R, Schmid T, Koeberle D, Zippelius A, Baues C, Mauch C, Tigges C, Kreuter A, Borggrefe J, von Bergwelt-Baildon M, Schlaak M.

Cancer Immunol Res. 2016 Sep 2;4(9):744-54. doi: 10.1158/2326-6066.CIR-15-0156. Epub 2016 Jul 27.


Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity.

Jais A, Solas M, Backes H, Chaurasia B, Kleinridders A, Theurich S, Mauer J, Steculorum SM, Hampel B, Goldau J, Alber J, Förster CY, Eming SA, Schwaninger M, Ferrara N, Karsenty G, Brüning JC.

Cell. 2016 May 5;165(4):882-95. doi: 10.1016/j.cell.2016.03.033. Epub 2016 Apr 28. Erratum in: Cell. 2016 Aug 25;166(5):1338-1340.


CD40-activated B cells induce anti-tumor immunity in vivo.

Wennhold K, Weber TM, Klein-Gonzalez N, Thelen M, Garcia-Marquez M, Chakupurakal G, Fiedler A, Schlösser HA, Fischer R, Theurich S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.

Oncotarget. 2017 Apr 25;8(17):27740-27753. doi: 10.18632/oncotarget.7720.


Physical exercise modulates the homeostasis of human regulatory T cells.

Weinhold M, Shimabukuro-Vornhagen A, Franke A, Theurich S, Wahl P, Hallek M, Schmidt A, Schinköthe T, Mester J, von Bergwelt-Baildon M, Bloch W.

J Allergy Clin Immunol. 2016 May;137(5):1607-1610.e8. doi: 10.1016/j.jaci.2015.10.035. Epub 2016 Jan 7. No abstract available.


Processing and MHC class II presentation of exogenous soluble antigen involving a proteasome-dependent cytosolic pathway in CD40-activated B cells.

Becker HJ, Kondo E, Shimabukuro-Vornhagen A, Theurich S, von Bergwelt-Baildon MS.

Eur J Haematol. 2016 Aug;97(2):166-74. doi: 10.1111/ejh.12699. Epub 2015 Dec 10.


Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.

Chakupurakal G, García-Márquez MA, Shimabukuro-Vornhagen A, Theurich S, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M.

Eur J Haematol. 2016 Aug;97(2):121-7. doi: 10.1111/ejh.12691. Epub 2015 Nov 16.


Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality--a single institution experience.

Chakupurakal G, Leitzke S, Langerbeins P, Schiller J, Schneider PM, Holtick U, Shimabukuro-Vornhagen A, Theurich S, Chemnitz J, Hallek M, von Bergwelt-Baildon M, Scheid C.

Ann Hematol. 2015 Oct;94(10):1717-25. doi: 10.1007/s00277-015-2449-1. Epub 2015 Aug 12.


FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission.

Holtick U, Shimabukuro-Vornhagen A, Chakupurakal G, Theurich S, Leitzke S, Burst A, Hallek M, von Bergwelt-Baildon M, Scheid C, Chemnitz JM.

Eur J Haematol. 2016 May;96(5):475-82. doi: 10.1111/ejh.12615. Epub 2015 Aug 25.


NK cells link obesity-induced adipose stress to inflammation and insulin resistance.

Wensveen FM, Jelenčić V, Valentić S, Šestan M, Wensveen TT, Theurich S, Glasner A, Mendrila D, Štimac D, Wunderlich FT, Brüning JC, Mandelboim O, Polić B.

Nat Immunol. 2015 Apr;16(4):376-85. doi: 10.1038/ni.3120. Epub 2015 Mar 2.


OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation.

Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, Fiedler A, Luznik L, Hellmich M, Wolf D, Hallek M, von Bergwelt-Baildon M, Scheid C.

Eur J Haematol. 2016 Jan;96(1):27-35. doi: 10.1111/ejh.12541. Epub 2015 Mar 16.


Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

Müller P, Martin K, Theurich S, von Bergwelt-Baildon M, Zippelius A.

Oncoimmunology. 2014 Aug 3;3(8):e954460. eCollection 2014.


Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Shimabukuro-Vornhagen A, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2015 May;94(2):179-88. doi: 10.1016/j.critrevonc.2014.12.007. Epub 2014 Dec 18. Review.


Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.

Huelsemann MF, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker HJ, Theurich S, von Bergwelt-Baildon M, Pallasch CP, Zahedi RP, Kashkar H, Reinhardt HC, Hallek M, Wendtner CM, Frenzel LP.

Leukemia. 2015 Apr;29(4):981-4. doi: 10.1038/leu.2014.320. Epub 2014 Nov 7. No abstract available.


Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.

Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M.

J Clin Oncol. 2016 Apr 20;34(12):e110-6. doi: 10.1200/JCO.2013.50.9471. Epub 2014 Oct 27. No abstract available.


Overcoming tumor-mediated immunosuppression.

Schlößer HA, Theurich S, Shimabukuro-Vornhagen A, Holtick U, Stippel DL, von Bergwelt-Baildon M.

Immunotherapy. 2014;6(9):973-88. doi: 10.2217/imt.14.58. Review.


Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity.

Shimabukuro-Vornhagen A, Zoghi S, Liebig TM, Wennhold K, Chemitz J, Draube A, Kochanek M, Blaschke F, Pallasch C, Holtick U, Scheid C, Theurich S, Hallek M, von Bergwelt-Baildon MS.

J Immunol. 2014 Nov 15;193(10):5294-305. doi: 10.4049/jimmunol.1203436. Epub 2014 Oct 13.


A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells.

Garcia-Marquez MA, Shimabukuro-Vornhagen A, Theurich S, Kochanek M, Weber T, Wennhold K, Dauben A, Dzionek A, Reinhard C, von Bergwelt-Baildon M.

Cytotherapy. 2014 Nov;16(11):1537-1544. doi: 10.1016/j.jcyt.2014.05.011.


CD4+ T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation.

Holtick U, Frenzel LP, Shimabukuro-Vornhagen A, Theurich S, Claasen J, Scheid C, von Bergwelt-Baildon M, Fröhlich H, Wendtner CM, Chemnitz JM.

Ann Hematol. 2015 Jan;94(1):129-37. doi: 10.1007/s00277-014-2166-1. Epub 2014 Aug 15.


Characterization of tumor-associated B-cell subsets in patients with colorectal cancer.

Shimabukuro-Vornhagen A, Schlößer HA, Gryschok L, Malcher J, Wennhold K, Garcia-Marquez M, Herbold T, Neuhaus LS, Becker HJ, Fiedler A, Scherwitz P, Koslowsky T, Hake R, Stippel DL, Hölscher AH, Eidt S, Hallek M, Theurich S, von Bergwelt-Baildon MS.

Oncotarget. 2014 Jul 15;5(13):4651-64.


Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Müller P, Martin K, Theurich S, Schreiner J, Savic S, Terszowski G, Lardinois D, Heinzelmann-Schwarz VA, Schlaak M, Kvasnicka HM, Spagnoli G, Dirnhofer S, Speiser DE, von Bergwelt-Baildon M, Zippelius A.

Cancer Immunol Res. 2014 Aug;2(8):741-55. doi: 10.1158/2326-6066.CIR-13-0198. Epub 2014 Apr 21.


Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults.

Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189. doi: 10.1002/14651858.CD010189.pub2. Review.


Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single german institution.

Chemnitz JM, Chakupurakal G, Bäßler M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Leitzke S, Von Bergwelt-Baildon MS, Scheid C.

ISRN Hematol. 2014 Mar 5;2014:853435. doi: 10.1155/2014/853435. eCollection 2014.


Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin.

Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, Theurich S, Hausen AC, Schmitz J, Brönneke HS, Estevez E, Allen TL, Mesaros A, Partridge L, Febbraio MA, Chawla A, Wunderlich FT, Brüning JC.

Nat Immunol. 2014 May;15(5):423-30. doi: 10.1038/ni.2865. Epub 2014 Mar 30.


Risk-adapted, treosulfan-based therapy with auto- and allo-SCT for relapsed/refractory aggressive NHL: a prospective phase-II trial.

Koenigsmann M, Casper J, Kahl C, Basara N, Sayer HG, Behre G, Theurich S, Christopeit M, Mohren M, Reichle A, Metzner B, Ganser A, Stadler M, Uharek L, Balleisen L, Hinke A, Hinke R, Niederwieser D.

Bone Marrow Transplant. 2014 Mar;49(3):410-5. doi: 10.1038/bmt.2013.199. Epub 2013 Dec 23.


[Pulmonary differentiation -/ATRA syndrome within the scope of therapy of acute promyelocytic leukemia (APL)].

Franke M, Theurich S, Beyer F, Persigehl T.

Rofo. 2014 Jun;186(6):615-7. doi: 10.1055/s-0033-1356047. Epub 2013 Dec 17. German. No abstract available.


Comment on "multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies".

Shimabukuro-Vornhagen A, Schlößer HA, Stippel DL, Theurich S, von Bergwelt-Baildon M.

J Immunol. 2013 Nov 1;191(9):4471. doi: 10.4049/jimmunol.1390052. No abstract available.


Allogeneic stem cell transplantation in patients with aggressive primary cutaneous T-cell lymphoma - a case series of the ADF working group "cutaneous lymphomas".

Moritz RK, Ditschkowski M, Klemke CD, Terras S, Schlaak M, Knorr M, Theurich S, Hegenbart U, Kremens B, Beelen DW, Stücker M, Kreuter A; working group "cutaneous lymphomas" of the Arbeitsgemeinschaft für Dermatologische Forschung (ADF), Germany.

J Dtsch Dermatol Ges. 2014 Jan;12(1):39-46. doi: 10.1111/ddg.12212. Epub 2013 Oct 17.


Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?

Garcia-Marquez MA, Shimabukuro-Vornhagen A, Theurich S, von Bergwelt-Baildon M.

Immunotherapy. 2013 Oct;5(10):1039-42. doi: 10.2217/imt.13.96.


Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma.

Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P.

Cochrane Database Syst Rev. 2013 Aug 29;(8):CD008908. doi: 10.1002/14651858.CD008908.pub3. Review.


CD30-targeted therapy with brentuximab vedotin and DLI in a patient with T-cell posttransplantation lymphoma: induction of clinical remission and cellular immunity.

Theurich S, Wennhold K, Wedemeyer I, Rothe A, Hübel K, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Scheid C, von Bergwelt-Baildon M.

Transplantation. 2013 Aug 15;96(3):e16-8. doi: 10.1097/TP.0b013e31829a9258. No abstract available.


18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.

Kahraman D, Theurich S, Rothe A, Kuhnert G, Sasse S, Scheid C, Dietlein M, Drzezga A, von Bergwelt-Baildon M, Kobe C.

Leuk Lymphoma. 2014 Apr;55(4):811-6. doi: 10.3109/10428194.2013.819575. Epub 2013 Jul 29.


CD40-activated B cells as antigen-presenting cells: the final sprint toward clinical application.

Wennhold K, Shimabukuro-Vornhagen A, Theurich S, von Bergwelt-Baildon M.

Expert Rev Vaccines. 2013 Jun;12(6):631-7. doi: 10.1586/erv.13.39. Review.


Anti-thymocyte globulins for post-transplant graft-versus-host disease prophylaxis-A systematic review and meta-analysis.

Theurich S, Fischmann H, Chakupurakal G, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Rothe A, Scheid C, Hallek M, Skoetz N, von Bergwelt-Baildon M.

Crit Rev Oncol Hematol. 2013 Oct;88(1):178-86. doi: 10.1016/j.critrevonc.2013.03.009. Epub 2013 Apr 2. Review.


Cyclin A1, a promising tumor antigen: the devil is in the amino acids.

Wennhold K, Theurich S, von Bergwelt-Baildon M.

Expert Rev Anticancer Ther. 2013 Mar;13(3):243-5. doi: 10.1586/era.12.175. No abstract available.


The ratio between dendritic cells and T cells determines whether prostaglandin E2 has a stimulatory or inhibitory effect.

Shimabukuro-Vornhagen A, Liebig TM, Koslowsky T, Theurich S, von Bergwelt-Baildon MS.

Cell Immunol. 2013 Jan;281(1):62-7. doi: 10.1016/j.cellimm.2013.01.001. Epub 2013 Jan 29.


Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M.

J Clin Oncol. 2013 Feb 10;31(5):e59-63. doi: 10.1200/JCO.2012.43.6832. Epub 2012 Dec 26. No abstract available.


Allogeneic hematopoietic stem cell transplantation: an option for long-term survival for patients with simultaneous appearance of myeloid and lymphatic malignancies.

Weber T, Ocheni S, Binder M, Theurich S, Scheid C, Schmid C, Müller LP, Christopeit M, Bacher U.

Acta Haematol. 2013;129(3):135-6. doi: 10.1159/000343422. Epub 2012 Nov 29. No abstract available.


Supplemental Content

Loading ...
Support Center